Recombinant TFPI/LACI/EPI Monoclonal Antibody (AN300196P)
For research use only.
| Verified Samples |
Verified Samples in WB: HepG2 in IF: HepG2 |
| Dilution | WB: 1:1000；ICC/IF: 1:100；IP: 1:20-1:50 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Human |
| Applications | WB, ICC/IF, IP |
| Clonality | Recombinant;Monoclonal |
| Immunogen | Recombinant Human TFPI Protein |
| Abbre | TFPI |
| Synonyms | NPN, NRP, Neuropilin, BDCA, TFPI, EPI, LACI, TFI, TFPI1, NPN1, BDCA4, CD304, Neuropilin1, NRP 1, Tissue factor pathway inhibitor, Extrinsic pathway inhibitor, Lipoprotein-associated coagulation inhibitor |
| Swissprot | |
| Calculated MW | 35 kDa |
| Observed MW |
40-55 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Secreted |
| Concentration | 1 mg/mL |
| Buffer | 0.2 μm filtered solution in PBS |
| Purification Method | Protein A |
| Research Areas | Cardiovascular |
| Clone | B114 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | This gene encodes a Kunitz-type serine protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. The product of this gene inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop. Inhibition of the encoded protein restores hemostasis in animal models of hemophilia. This gene encodes multiple protein isoforms that differ in their inhibitory activity, specificity and cellular localization. [provided by RefSeq, Jul 2016] |
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
No files available. Please enter the correct identification code in the search area to query the relevant documents.
| Title | Status | Valid until | Action | |
|---|---|---|---|---|
| {{v.文件名}} | {{v.status_str}} | {{v.timestamp_str}} | Download | / |
*Note：Please download the relevant files within the validity period. After expiration, file preview and download will not be available on the page.
Videos
Resources
Contact with Us
Houston, Texas, 77079, USA
